AKTIP Loss Is Enriched in ERα-Positive Breast Cancer for Tumorigenesis and Confers Endocrine Resistance

The authors identified that loss of AKTIP, which is located on 16q12.2, drove tumorigenesis of estrogen receptor alpha (ERα)-positive, but not ERα-negative, breast cancer cells and was associated with poor prognosis of patients with ERα-positive breast cancer.